Key investment points:
This week, SW pharmaceutical and biological industry lost the CSI 300 index. From April 18 to April 22, 2022, SW pharmaceutical and biological industry fell by 7.34%, underperforming the CSI 300 index by about 3.15 percentage points in the same period. Among the three-level segments of SW pharmaceutical and biological industry, all segments recorded negative returns. Hospitals, offline pharmacies, chemical agents, medical R & D outsourcing, medical consumables, blood products, other biological products, in vitro diagnosis, traditional Chinese Medicine III, APIs, pharmaceutical circulation, medical equipment and vaccines decreased by 3.00%, 4.72%, 6.24%, 6.58%, 6.78%, 6.91%, 7.44%, 8.01%, 8.30%, 8.30%, 8.78%, 8.92% and 10.31% respectively.
This week, the pharmaceutical and biological industry had a net inflow of 102 million yuan. From April 18 to April 22, 2022, the land stock connect had a net inflow of 445 million yuan, of which the Shanghai Stock connect had a net outflow of 1.328 billion yuan and the Shenzhen Stock connect had a net inflow of 1.773 billion yuan. In the Shenwan industry, the net inflow of power equipment ranks first and the net outflow of Electronics ranks first. This week, the pharmaceutical and biological industry had a net inflow of 102 million yuan, which was slightly higher than that of last week.
Industry news. On April 23, the World Health Organization released its latest report: since the UK reported 74 cases of unexplained acute hepatitis in children on April 15, more countries have reported new cases. As of 21 April, 11 countries in the WHO European region and 1 country in the Americas region had reported at least 169 cases of unexplained acute hepatitis in children.
Maintain the recommended rating of the industry. The local sporadic epidemic in China is still continuing. Under China’s dynamic zero epidemic prevention policy, the demand for relevant anti epidemic products is still relatively large. We pay attention to the relevant beneficiary targets such as antigen detection industrial chain, covid-19 vaccine industrial chain and relevant anti epidemic material industrial chain. Close to the peak of financial disclosure, pay attention to the relevant stocks whose performance is expected to exceed the expected performance. A CXO company that is expected to keep a high growth in the first quarter of the first quarter is expected to be a CXO company that is expected to keep a high growth in the first quarter. A CXO company that is expected to keep a high growth in the first quarter of the first quarter is expected to keep a high growth in the first quarter. For example, a CXO company that is expected to keep a high growth in the first quarter of the first quarter. A CXO company is a CXO company that is expected to keep a high growth in the first quarter of the first quarter of the first quarter of the first quarter of the first quarter of the first quarter of the first quarter of the first quarter of the first quarter. A high growth is expected to be expected in Poten Environment Group Co.Ltd(603603) 2525259 8202), etc; Covid-19 antigen detection reagent related enterprises Guangzhou Wondfo Biotech Co.Ltd(300482) ( Guangzhou Wondfo Biotech Co.Ltd(300482) ), Zhejiang Orient Gene Biotech Co.Ltd(688298) Zhejiang Orient Gene Biotech Co.Ltd(688298) ; Several covid-19 vaccine pipelines are arranged, and the mRNA vaccine under development is expected to be the first approved Walvax Biotechnology Co.Ltd(300142) ( Walvax Biotechnology Co.Ltd(300142) ) in China. Medical device leader Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) ( Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) ), medical beauty leader Imeik Technology Development Co.Ltd(300896) ( Imeik Technology Development Co.Ltd(300896) ), OK mirror leader Autek China Inc(300595) ( Autek China Inc(300595) ), ophthalmic device leader Eyebright Medical Technology(Beijing) Co.Ltd(688050) ( Eyebright Medical Technology(Beijing) Co.Ltd(688050) ), etc. with relatively reasonable valuation; In the medium term, chain medical leaders Aier Eye Hospital Group Co.Ltd(300015) ( Aier Eye Hospital Group Co.Ltd(300015) ), Topchoice Medical Co.Inc(600763) ( Topchoice Medical Co.Inc(600763) ), which are expected to benefit from aging and strong endogenous growth.
Risk tip: the demand for covid-19 antigen detection has not increased as expected, the industry competition has intensified, product price reduction, product safety and quality risk, policy risk, repeated epidemic, and the R & D progress is lower than expected.
